The Allurion Program is suited for people who are unable to achieve their weight-loss goals by dieting alone or for those who do not want to, or cannot, undergo invasive surgery or endoscopy
The virtual event will be attended by representatives from state & district health administration, corporates, industries, civil society, and NGOs as the country reiterates its commitment towards TB elimination by 2025
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
The capital expansion program commenced in June 2022 and is expected to complete in 2024
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
